2022
DOI: 10.1186/s12868-022-00734-8
|View full text |Cite
|
Sign up to set email alerts
|

Sustained delivery of chABC improves functional recovery after a spine injury

Abstract: Introduction Chondroitinase ABC (chABC) is an enzyme could improve regeneration and thereby improving functional recovery of spinal cord injury (SCI) in rodent models. Degradation of the active enzyme and diffusion away from the lesion are the causes of using hydrogels as a scaffold to deliver the chABC into the lesion site. In this meta-analysis, we investigated the effects of chABC embedded in a scaffold or hydrogel on the functional recovery after SCI. Method … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 19 publications
(7 citation statements)
references
References 64 publications
0
5
0
Order By: Relevance
“…Cellular/molecular therapeutic strategies currently investigated for SCI regeneration target the glial scar and promote regeneration in the following ways: (1) targeting scar formation; (2) resolving the mature scar; (3) cell transplantation; and (4) endogenous cell reprogramming. Locomotor functional recovery has been observed in rodent SCI model behavioral assessments of therapeutics in each of these major groups [ 86 , 95 , 119 , 143 , 147 ]. However, few therapeutics successfully translate to clinical trials; thus, SCI remains a debilitating injury.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Cellular/molecular therapeutic strategies currently investigated for SCI regeneration target the glial scar and promote regeneration in the following ways: (1) targeting scar formation; (2) resolving the mature scar; (3) cell transplantation; and (4) endogenous cell reprogramming. Locomotor functional recovery has been observed in rodent SCI model behavioral assessments of therapeutics in each of these major groups [ 86 , 95 , 119 , 143 , 147 ]. However, few therapeutics successfully translate to clinical trials; thus, SCI remains a debilitating injury.…”
Section: Discussionmentioning
confidence: 99%
“…CSPGs are ubiquitous and abundant around the scar and possess a known degradation enzyme [ 91 , 93 , 94 ]. The upregulation or administration of CSPG enzyme ChABC, a bacterial lyase which degrades CSPG side chains, yielded functional recovery in a rodent SCI model [ 92 , 95 ]. However, the high enzyme degradation rate (within 24 h) was considered to be a major limiting factor preceding clinical trials, thus methods of biotechnology are being employed to extend the stability of the enzyme around the injury site.…”
Section: Current Research In Therapeutic Interventionsmentioning
confidence: 99%
“…As reported previously, early therapeutic approaches in the management of SCI lead to better outcomes and fewer postoperative complications, both in clinical and preclinical evidence. [68][69][70][71] Even though we aimed at summarizing the evidence from both animal and human populations, our search resulted in no clinical research that would meet our inclusion criteria. The chronic shoulder pain and generally perceived pain that was evaluated in previous RCTs could have etiologies other than neuropathic pain, and their inclusion is considered an ancillary analysis in this meta-analysis.…”
Section: Discussionmentioning
confidence: 99%
“…The research at present focuses on the therapeutic strategies that target these inhibitory pathways. For example, Chondroitinase ABC degrades CSPGs, improving axonal regeneration in animal models [ 102 , 103 , 104 ]. Pharmaceutical agents targeting RhoA/ROCK and other signaling pathways have also shown potential [ 105 , 106 ].…”
Section: Current Challenges In the Treatment Of Scismentioning
confidence: 99%